Tubulysine derivatives

1. A compound of Formula (IV),

wherein

R 2 is C 1 -C 4 alkyl;

R 6 is C 1 -C 6 alkyl;

R 7 is C 1 -C 6 alkyl, CH 2 -Phenyl, CH 2 OR 19 or CH 2 OCOR 20 , wherein R 19 is alkyl, R 20 is phenyl, or CH 2 -Phenyl;

R 9 is C 1 -C 6 alkyl;

R 10 ° is H, OH, O-alkyl or O-acetyl;

f is 1 or 2;

R 11 is a group of the Formula (II)

wherein

R 15 is a group of the formula

wherein R 21 is H, halogen, OH, NO 2 NH 2 , CN, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxy, alkyl amino or dialkyl amino;

R 16 is H or CH 3 ;

R 17 is CO 2 H, CO 2 R 18 , CONHNH 2 , OH, NH 2 , SH or an optionally substituted heteroalkyl or heterocycloalkyl group, wherein R 18 is an optionally substituted alkyl, heteroalkyl or heterocycloalkyl group; and

p is 0, 1, 2 or 3;

or a pharmacologically acceptable salt, a solvate, a hydrate or a pharmacologically acceptable formulation thereof.

2. The compound according to claim 1 , wherein R 2 is a methyl group.

3. The compound according to claim 1 , wherein R 6 is an isobutyl group.

4. The compound according to claim 1 , wherein p is 1.

5. The compound according to claim 1 , wherein R 11 has the following structure:

wherein

R 21 is H, OH, halogen, NH 2 , alkyloxy, phenyl, alkyl amino or dialkyl amino;

R 16 is H or CH 3 ;

R 17 is CO 2 H, CO 2 R 18 , CONHNH 2 , OH, NH 2 , SH or an optionally substituted heteroalkyl or heterocycloalkyl group, wherein R 18 is an optionally substituted alkyl, heteroalkyl or heterocycloalkyl group; and

p is 0, 1,2 or 3.

6. A pharmaceutical composition comprising a compound according to claim 1 and optionally one or more carriers and/or adjuvants.

7. A method for treating a subject suffering from or susceptible to cancer selected from the group consisting of ovarian, colon, breast and lung cancer, comprising administering to the subject a compound of claim 1 .

8. The method of claim 7 wherein the subject is suffering from cancer.

9. A method for providing surface modifications of a plastic or metal implant, comprising use of a compound of claim 1 .

10. The method of claim 9 wherein the plastic or metal implant is treated with the compound.

11. The method of claim 9 wherein the plastic or metal implant comprising the compound is implanted into a subject.

12. A compound of the following formula:

wherein

R 7 is C 1 -C 6 alkyl, CH 2 Ph, CH 2 OCH 2 CH(CH 3 ) 2 , CH 2 OCOCH 2 Ph, or CH 2 OCOPh;

R 10 is H, O-alkyl, OH or OAc;

R 16 is CH 3 or H;

R 17 is COOH, CONHNH 2 , OH, NH 2 , CH 2 OH, CH 2 NH 2 or CH 2 SH; and

R 21 is H, F, OH, NH 2 , CH 3 , OMe or Ph;

or a pharmacologically acceptable salt, a solvate, a hydrate or a pharmacologically acceptable formulation thereof.

13. A pharmaceutical composition comprising a compound according to claim 12 and optionally one or more carriers and/or adjuvants.

14. A method for preparing conjugates comprising at least one compound of Formula (I) or (IV) and a biological molecule, e.g. oligo or poly saccharide, monoclonale antibody, lectine, PSA (prostata specific antigen) or peptidic vector, hormone, vitamin, lipid or a synthetic polymer and optionally also a linker or polymer of natural or unnatural origin, such as a pegylated polymer, starch, cyclodextrine or a mixture of a synthetic polymer with a biological molecule.